Literature DB >> 26243484

Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients.

Kelly Fellows1, Tomas Uher2, Richard W Browne3, Bianca Weinstock-Guttman4, Dana Horakova2, Helena Posova5, Manuela Vaneckova6, Zdenek Seidl6, Jan Krasensky6, Michaela Tyblova2, Eva Havrdova2, Robert Zivadinov7, Murali Ramanathan8.   

Abstract

The purpose of this work was to investigate the associations of serum cholesterol and apolipoproteins with measures of blood-brain barrier (BBB) permeability and CNS inflammation following the first clinical demyelinating event. This study included 154 patients [67% female; age, 29.5 ± 8.2 years (mean ± SD)] enrolled in a multi-center study of interferon β1-a treatment following the first demyelinating event. Blood and cerebrospinal fluid (CSF) were obtained at screening prior to treatment. A comprehensive serum lipid profile and multiple surrogate markers of BBB breakdown and CNS immune activity were obtained. Higher levels of serum HDL cholesterol (HDL-C) and ApoA-I were associated with lower CSF total protein level, CSF albumin level, albumin quotient, and CSF IgG level (all P ≤ 0.001 for HDL-C and all P < 0.01 for ApoA-I). HDL-C was also associated with CSF CD80+ (P < 0.001) and with CSF CD80+CD19+ (P = 0.007) cell frequencies. Higher serum HDL is associated with lower levels of BBB injury and decreased CD80+ and CD80+CD19+ cell extravasation into the CSF. HDL may potentially inhibit the initiation and/or maintenance of pathogenic BBB injury following the first demyelinating event.
Copyright © 2015 by the American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  apolipoproteins; cholesterol; clinically isolated syndrome; high density lipoprotein

Mesh:

Substances:

Year:  2015        PMID: 26243484      PMCID: PMC4583090          DOI: 10.1194/jlr.M060970

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  38 in total

Review 1.  Blood-brain barrier disruption in multiple sclerosis.

Authors:  Alireza Minagar; J Steven Alexander
Journal:  Mult Scler       Date:  2003-12       Impact factor: 6.312

2.  Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later.

Authors:  Tomas Uher; Dana Horakova; Michaela Tyblova; David Zeman; Eva Krasulova; Katerina Mrazova; Zdenek Seidl; Manuela Vaneckova; Jan Krasensky; Bianca Weinstock-Guttman; Murali Ramanathan; Eva Havrdova; Robert Zivadinov
Journal:  Mult Scler       Date:  2015-09-11       Impact factor: 6.312

3.  Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.

Authors:  J S Alexander; M K Harris; S R Wells; G Mills; K Chalamidas; V C Ganta; J McGee; M H Jennings; E Gonzalez-Toledo; A Minagar
Journal:  Mult Scler       Date:  2010-07       Impact factor: 6.312

4.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

5.  Paediatric and adult multiple sclerosis: age-related differences and time course of the neuroimmunological response in cerebrospinal fluid.

Authors:  H Reiber; M Teut; D Pohl; K M Rostasy; F Hanefeld
Journal:  Mult Scler       Date:  2009-12-07       Impact factor: 6.312

6.  Accuracy and biological variation of human serum paraoxonase 1 activity and polymorphism (Q192R) by kinetic enzyme assay.

Authors:  Richard W Browne; Stephen T Koury; Susan Marion; Gregory Wilding; Paola Muti; Maurizio Trevisan
Journal:  Clin Chem       Date:  2006-12-21       Impact factor: 8.327

Review 7.  HDL and cholesterol handling in the brain.

Authors:  Cecilia Vitali; Cheryl L Wellington; Laura Calabresi
Journal:  Cardiovasc Res       Date:  2014-06-06       Impact factor: 10.787

Review 8.  Apolipoprotein A-II: evaluating its significance in dyslipidaemia, insulin resistance, and atherosclerosis.

Authors:  Dick C Chan; Theodore W K Ng; Gerald F Watts
Journal:  Ann Med       Date:  2011-04-18       Impact factor: 4.709

9.  Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease.

Authors:  Daria Trabattoni; Marina Saresella; Michela Pacei; Ivana Marventano; Laura Mendozzi; Marco Rovaris; Domenico Caputo; Manuela Borelli; Mario Clerici
Journal:  J Immunol       Date:  2009-09-30       Impact factor: 5.422

10.  Dyslipidemia and blood-brain barrier integrity in Alzheimer's disease.

Authors:  Gene L Bowman; Jeffrey A Kaye; Joseph F Quinn
Journal:  Curr Gerontol Geriatr Res       Date:  2012-05-13
View more
  13 in total

1.  Interdependence of oxysterols with cholesterol profiles in multiple sclerosis.

Authors:  Shreya Mukhopadhyay; Kelly Fellows; Richard W Browne; Prachi Khare; Sandhya Krishnan Radhakrishnan; Jesper Hagemeier; Bianca Weinstock-Guttman; Robert Zivadinov; Murali Ramanathan
Journal:  Mult Scler       Date:  2016-09-28       Impact factor: 6.312

Review 2.  Interactions of Lipids, Lipoproteins, and Apolipoproteins with the Blood-Brain Barrier.

Authors:  Elizabeth M Rhea; William A Banks
Journal:  Pharm Res       Date:  2021-09-13       Impact factor: 4.200

3.  Influential Factors, Treatment and Prognosis of Autoimmune Encephalitis Patients With Poor Response to Short-Term First-Line Treatment.

Authors:  Fei Liu; Bingbing Zhang; Teng Huang; Baojie Wang; Chunjuan Wang; Maolin Hao; Shougang Guo
Journal:  Front Neurol       Date:  2022-04-14       Impact factor: 4.003

4.  Twelve Weeks of Medium-Intensity Exercise Therapy Affects the Lipoprotein Profile of Multiple Sclerosis Patients.

Authors:  Winde Jorissen; Tim Vanmierlo; Inez Wens; Veerle Somers; Bart Van Wijmeersch; Jeroen F Bogie; Alan T Remaley; Bert O Eijnde; Jerome J A Hendriks
Journal:  Int J Mol Sci       Date:  2018-01-08       Impact factor: 5.923

5.  Relapsing-remitting multiple sclerosis patients display an altered lipoprotein profile with dysfunctional HDL.

Authors:  Winde Jorissen; Elien Wouters; Jeroen F Bogie; Tim Vanmierlo; Jean-Paul Noben; Denis Sviridov; Niels Hellings; Veerle Somers; Roland Valcke; Bart Vanwijmeersch; Piet Stinissen; Monique T Mulder; Alan T Remaley; Jerome J A Hendriks
Journal:  Sci Rep       Date:  2017-02-23       Impact factor: 4.379

Review 6.  Steroid Transport, Local Synthesis, and Signaling within the Brain: Roles in Neurogenesis, Neuroprotection, and Sexual Behaviors.

Authors:  Nicolas Diotel; Thierry D Charlier; Christian Lefebvre d'Hellencourt; David Couret; Vance L Trudeau; Joel C Nicolau; Olivier Meilhac; Olivier Kah; Elisabeth Pellegrini
Journal:  Front Neurosci       Date:  2018-02-20       Impact factor: 4.677

7.  The pleiotropic vasoprotective functions of high density lipoproteins (HDL).

Authors:  Guilaine Boyce; Emily Button; Sonja Soo; Cheryl Wellington
Journal:  J Biomed Res       Date:  2017-05-26

8.  Lipid profile is associated with decreased fatigue in individuals with progressive multiple sclerosis following a diet-based intervention: Results from a pilot study.

Authors:  Kelly Fellows Maxwell; Terry Wahls; Richard W Browne; Linda Rubenstein; Babita Bisht; Catherine A Chenard; Linda Snetselaar; Bianca Weinstock-Guttman; Murali Ramanathan
Journal:  PLoS One       Date:  2019-06-18       Impact factor: 3.240

Review 9.  The physiology of foamy phagocytes in multiple sclerosis.

Authors:  Elien Grajchen; Jerome J A Hendriks; Jeroen F J Bogie
Journal:  Acta Neuropathol Commun       Date:  2018-11-19       Impact factor: 7.801

10.  High-fat diet protects the blood-brain barrier in an Alzheimer's disease mouse model.

Authors:  Shirin Elhaik Goldman; David Goez; David Last; Sharone Naor; Sigal Liraz Zaltsman; Inbal Sharvit-Ginon; Dana Atrakchi-Baranes; Chen Shemesh; Rachel Twitto-Greenberg; Shoval Tsach; Roni Lotan; Alicia Leikin-Frenkel; Aviv Shish; Yael Mardor; Michal Schnaider Beeri; Itzik Cooper
Journal:  Aging Cell       Date:  2018-08-06       Impact factor: 9.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.